Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106262 · ClinicalTrials.gov registry record · Phase 2
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
A Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00106262: Clinical Trial Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
NCT00106262 is a Phase 2 study that was terminated before completion, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106262, a Phase 2 study, was terminated before completion, sponsored by Women and Infants Hospital of Rhode Island.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is conducting an evaluation of two chemotherapy drugs, Velcade and Irinotecan, in women with advanced, recurrent, or metastatic cervical cancer, vaginal cancer, or vulvar cancer. Patients with cervical cancer may have received a platinum-containing treatment as systemic therapy without radiation, but is not required.
Interventions
- DRUG Irinotecan
- DRUG Velcade (bortezomib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Why NCT00106262 stopped before completion
NCT00106262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT00106262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00106262 about?
NCT00106262 is a clinical study titled "Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer". This study is conducting an evaluation of two chemotherapy drugs, Velcade and Irinotecan, in women with advanced, recurrent, or metastatic cervical cancer, vaginal cancer, or vulvar cancer. Patients with cervical cancer may have received a platinum-containing treatment as systemic therapy without ra...
What is the current status of trial NCT00106262?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2005-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00106262?
The interventions under investigation include: Irinotecan (DRUG), Velcade (bortezomib) (DRUG).
Who is sponsoring clinical trial NCT00106262?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00106262's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia